Similar strategies could target NT receptors, as demonstrated by Schulz et al., who found that a 177Lu-labeled NTR1-targeting agent effectively delayed tumor growth in NTR1-positive colon carcinoma xenografts, with significant reductions in tumor size [68]. Here, NTSR1 is linked to neoplasm.